Agenda

Sponsored by Daiichi Sankyo, Inc. & AstraZeneca

This is a Non CME/CE Presentation.

This industry sponsored program will share evidence from routine clinical practice, which complements findings from the randomized clinical trials PALOMA-2 and PALOMA-3. Real-world data for HR+/HER2- aBC/mBC patients treated with CDK4/6 inhibitor combination therapy will also be evaluated. 

Sponsored by Pfizer

This is a Non CME/CE Presentation.

Sponsored by AstraZeneca

This is a Non CME/CE Presentation.

9:00 am CT | Morning Welcome/Session I Introduction
Elizabeth A. Morris, MD

9:05 am CT | Individualized Breast Cancer Risk Assessment 
Heather Hampel, MS, CGC

9:35 am CT | Implications of Density in Breast Cancer Risk
Stamatia Destounis, MD, FACR

10:05 am CT | Clinical Application and Predictive Value of the Breast Imaging Reporting and Data System (BI-RADS®) 
Wendy DeMartini, MD

10:55 am CT | What’s New In Mammography?
Janice S. Sung, MD

11:25 am CT | Standard Mammography vs Breast MRI for Screening
Jessica W. T. Leung, MD

11:55 am CT | Screening Guidelines Panel
Elizabeth A. Morris, MD, Moderator
Wendy DeMartini, MD
Stamatia Destounis, MD, FACR
Heather Hampel, MS, CGC
Jessica W. T. Leung, MD
Janice S. Sung, MD

Supported by an independent educational grant from Bayer
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 3.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Radiology Technologists
This activity will be submitted to the American Society of Radiologic Technologists (ASRT) for 3.0 hours of ARRT Category A continuing education credit.

9:30 am CT | Conference Welcome
Joyce Ann O'Shaughnessy, MD

9:35 am CT | Session III Introduction
Erika P. Hamilton, MD

9:40 am CT | Multidisciplinary Approach to Genomic Assays: What Have We Learned?
Sunil Badve, MD, FCRPath
Kevin Kalinsky, MD

10:10 am CT | Making Adjuvant Treatment Decisions Based on Risk of Recurrence in HR-Positive Early Breast Cancer
Joyce Ann O'Shaughnessy, MD
William Gradishar, MD

10:40 am CT | Test Your Knowledge: Clinical Considerations in the Treatment of Early HR-Positive Breast Cancer
Erika P. Hamilton, MD, Moderator
Sunil Badve, MD, FCRPath
Sarah Donahue, MPH, NP, AOCNP
William Gradishar, MD
Kevin Kalinsky, MD
Joyce Ann O'Shaughnessy, MD

11:10 am CT | Audience Q&A and Panel Discussion
Erika P. Hamilton, MD, Moderator
Sunil Badve, MD, FCRPath
Sarah Donahue, MPH, NP, AOCNP
William Gradishar, MD
Kevin Kalinsky, MD
Joyce Ann O'Shaughnessy, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Lilly
Supported by an independent educational grant from Gilead Sciences, Inc.
Supported by an independent educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-173-L01-P.

3:15 pm CT | Session V Introduction
Komal Jhaveri, MD

3:20 pm CT | ABCs of HR-Positive Breast Cancer: Review of PI3K- and AKT-Directed Therapies
Komal Jhaveri, MD

3:50 pm CT | Antibody-Drug Conjugates in HR-Positive Breast Cancer
Paolo Tarantino, MD
Jonathan W. Malara, PharmD, BCOP

4:20 pm CT | Managing Treatment Toxicities: Nursing and Pharmacist Perspectives
Kristina Byers, PharmD, BCOP
Sarah Donahue, MPH, NP, AOCNP

4:50 pm CT | Audience Q&A and Panel Discussion
Komal Jhaveri, MD, Moderator
Kristina Byers, PharmD, BCOP
Sarah Donahue, MPH, NP, AOCNP
Jonathan W. Malara, PharmD, BCOP
Paolo Tarantino, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Lilly
Supported by an independent educational grant from Gilead Sciences, Inc.
Supported by an independent educational grant from Seagen, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-175-L01-P.

12:50 pm CT | Session VII Introduction
Reshma L. Mahtani, DO

12:55 pm CT | Treatment Sequencing for HER2-Positive Metastatic Breast Cancer
Alberto Montero, MD, MBA

1:25 pm CT | Emerging HER2-Directed ADCs for HER2-Positive Breast Cancer
A. Jo Chien, MD

1:40 pm CT | Novel TKIs, Bispecific Antibodies, and Immunotherapy
Paolo Tarantino, MD

1:55 pm CT | Mitigation and Management of Toxicities in HER2-Positive Breast Cancer: Nursing and Pharmacist Perspectives
Allison Butts, PharmD, BCOP
Jennifer McKenna, RN, MSN

2:25 pm CT | Audience Q&A and Panel Discussion
Reshma L. Mahtani, DO, Moderator
Allison Butts, PharmD, BCOP
A. Jo Chien, MD
Jennifer McKenna, RN, MSN
Alberto Montero, MD, MBA
Paolo Tarantino, MD

Supported by an independent educational grant from Daiichi Sankyo
Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-178-L01-P.

8:15 am CT | Morning Welcome/Session IX Introduction
Sara A. Hurvitz, MD

8:20 am CT | Updates on Systemic Therapy in Triple Negative Breast Cancer: Neoadjuvant/Adjuvant Therapies
Jennifer Litton, MD
Jonathan W. Malara, MD

9:00 am CT | Circulating Tumor DNA (ctDNA) and Minimal Residual Disease in Triple Negative Breast Cancer
Massimo Cristofanilli, MD, FACP
Denise Yardley, MD

9:30 am CT | Case Review: Testing Your Knowledge on Early Triple Negative Breast Cancer Management
Sara A. Hurvitz, MD, Moderator
Massimo Cristofanilli, MD, FACP
Jennifer Litton, MD
Jonathan Malara, MD
Denise Yardley, MD

10:00 am CT | Audience Q&A and Panel Discussion
Sara A. Hurvitz, MD, Moderator
Massimo Cristofanilli, MD, FACP
Jennifer Litton, MD
Jonathan Malara, MD
Denise Yardley, MD

Supported by an independent educational grant from Exact Sciences
Supported by an independent educational grant from Gilead Sciences, Inc.

ACCREDITATION STATEMENT 
In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

For Physicians
Medscape, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For Nurses
Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; final contact hours in the area of pharmacology will be posted on the conference platform.

For Pharmacists
Medscape designates this continuing education activity for Knowledge-based 2.0 contact hours and 0.200 CEUs. See individual session Universal Activity Number: JA0007105-0000-22-179-L01-P.